[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100577619":3},{"organization":4,"outcomesModule":7,"designInfo":16,"detailedDescription":27,"studyPopulation":11,"armGroups":28,"interventions":39,"overallOfficials":48,"centralContacts":53,"locations":59,"responsibleParty":77,"collaborators":11,"id":79,"slug":11,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":11,"eligibilityCriteria":84,"healthyVolunteers":80,"sex":85,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":11,"studyType":91,"phases":92,"briefSummary":94,"conditions":95,"keywords":11,"overallStatus":61,"whyStopped":11,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Jemincare","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Percentage Change of TKV from baseline to Week 52",null,"52 weeks",[14],{"measure":15,"description":11,"timeFrame":12},"Annual rate of change in eGFR from baseline to Week 52",{"allocation":17,"interventionModel":18,"interventionModelDescription":11,"primaryPurpose":19,"observationalModel":11,"timePerspective":11,"maskingInfo":20},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":21,"maskingDescription":11,"whoMasked":22},"QUADRUPLE",[23,24,25,26],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR","Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JMKX003142 in Participants with Rapidly Progressive ADPKD",[29,34],{"label":30,"type":31,"description":11,"interventionNames":32},"JMKX003142","EXPERIMENTAL",[33],"Drug: JMKX003142 will be administered orally",{"label":35,"type":36,"description":11,"interventionNames":37},"placebo","PLACEBO_COMPARATOR",[38],"Drug: Plcacebo",[40,44],{"type":41,"name":42,"description":42,"armGroupLabels":43,"otherNames":11},"DRUG","JMKX003142 will be administered orally",[30],{"type":41,"name":45,"description":46,"armGroupLabels":47,"otherNames":11},"Plcacebo","matched to JMKX003142",[35],[49],{"name":50,"affiliation":51,"role":52},"Hong Zhang, Ph.D","Peking University First Hospital","STUDY_CHAIR",[54],{"name":55,"role":56,"phone":57,"phoneExt":11,"email":58},"xiaojun zhou","CONTACT","+8613717736760","zhouxiaojun@jemincare.com",[60],{"facility":51,"status":61,"city":62,"state":63,"zip":64,"country":65,"countryCode":66,"cosmosGeoPoint":67,"geoPoint":72,"contacts":73},"RECRUITING","Beijing","Beijing Municipality","100034","China","CN",{"type":68,"coordinates":69},"Point",[70,71],116.39723,39.9075,{"lat":71,"lon":70},[74],{"name":50,"role":56,"phone":75,"phoneExt":11,"email":76},"010-83572211","hongzh@bjmu.edu.cn",{"type":78,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100577619",false,"NCT06800651","Trial of JMKX003142 in Participants With Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)","A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JMKX003142 in Participants With Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)","Inclusion Criteria:\n\n* Able to understand the procedures of this trial and provide written informed consent voluntarily;\n* Age between 18 to 55 years, male or female;\n* ADPKD diagnostic criteria were met before randomization;\n* Rapidly progressive ADPKD criteria were met.\n\nExclusion Criteria:\n\n* 12 weeks prior to screening, patients had taken tolvaptan or another ADPKD improvers, or patients who were assessed by the investigator to be likely to use diuretic during the trial period;\n* Praticipants who are unable to feel thirst, or have difficulty with fluid\u002Ffood intake;\n* Patients who have previously received decompression surgery for renal cysts; or who received major surgery within 12 weeks before signing the ICF;\n* The investigator think that the praticipant is unable to comply with the requirements of the trial or cannot be evaluated by the trial.","ALL","18 Years","55 Years",{"count":89,"type":90},135,"ESTIMATED","INTERVENTIONAL",[93],"PHASE2","A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JMKX003142 in Participants with Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)",[96],"ADPKD (Autosomal Dominant Polycystic Kidney Disease)","2025-06-30",{"date":99,"type":100},"2025-07-03","ACTUAL",{"date":102,"type":100},"2025-03-13",{"date":104,"type":90},"2027-05-30",{"name":5,"class":6},1]